Abstract:Purpose of ReviewHere, we systematically review the published literature indicating that aberrant regulation of Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling was associated with the autoimmune disorders, rheumatoid arthritis, systemic lupus erythematosus, psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel diseases, and ankylosing spondylitis.Pertinent FindingsThe autoimmune disorders discussed in this review are characterized by several alterations resulting in abnormal JAK-STAT signaling. These abnormalities in JAK-STAT signaling include (1) constitutive activation of both the interleukin-6(IL-6)/interleukin-6 receptor (IL-6R) canonical and IL-6 trans-signaling pathway, the latter involving soluble IL-6R; (2) the hyperactivation of JAK/STAT signaling as a response to the significantly elevated levels of pro-inflammatory “immunocytokines”, exemplified by IL-6, IL-15, IL-17, IL-23, interferon-γ; and (3) the reduced activity of the negative regulators of JAK-STAT signaling, including suppressor of cytokine signaling and protein inhibitor of activated STATs as well as protein tyrosine phosphatases-1, -2, which was shown to inhibit STAT-signaling.SummaryThe involvement of abnormal JAK-STAT signaling in autoimmune disorders has led to the development of JAK small molecule inhibitors (SMIs), such as tofacitinib, ruxolitinib, and baricitinib for the therapy of rheumatoid arthritis, psoriasis/psoriatic arthritis, and Crohn’s disease. However, the extent to which treatment of these diseases with JAK SMIs will result in blunting the “cross-talk” between the JAK-STAT signaling pathway and the other signaling pathways known to participate in autoimmune disorders remains to be determined, involving the mitogen-activated protein kinase pathway and the phosphatidylinositide/Akt/mechanistic target of rapamycin signaling pathway.

JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

Pain in axial spondyloarthritis: role of the JAK/STAT pathway

JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions

Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy

Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

JAK Inhibitors: Prospects in Connective Tissue Diseases

The Role of STATs in Inflammation and Inflammatory Diseases

Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease

Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship

SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis

The JAK-STAT Pathway and the JAK Inhibitors

Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?